Alteration of the Exhaled Volatile Organic Compound Pattern in Colorectal Cancer Patients after Intentional Curative Surgery-A Prospective Pilot Study
- PMID: 37835479
- PMCID: PMC10571749
- DOI: 10.3390/cancers15194785
Alteration of the Exhaled Volatile Organic Compound Pattern in Colorectal Cancer Patients after Intentional Curative Surgery-A Prospective Pilot Study
Abstract
As current follow-up modalities for colorectal carcinoma (CRC) have restricted sensitivity, novel diagnostic tools are needed. The presence of CRC changes the endogenous metabolism, resulting in the release of a specific volatile organic compounds (VOC) pattern that can be detected with an electronic nose or AeonoseTM. To evaluate the use of an electronic nose in the follow-up of CRC, we studied the effect of curative surgery on the VOC pattern recognition using AeonoseTM. A prospective cohort study was performed, in which 47 patients diagnosed with CRC were included, all of whom underwent curative surgical resection. Breath testing was performed before and after surgery using the AeonoseTM. A machine learning model was developed by discerning between the 94 pre-and postoperative breath samples. The training model differentiated between the pre-and postoperative CRC breath samples with a sensitivity and specificity of 0.78 (95%CI 0.61-0.90) and 0.73 (95%CI 0.56-0.86), respectively, with an accuracy of 0.76 (95%CI 0.66-0.85), and an area under the curve of 0.79 (95%CI 0.68-0.89). The internal validation of the test set resulted in an accuracy of 0.75 (95%CI 0.51-0.91) and AUC of 0.82 (95%CI 0.61-1). In conclusion, our results suggest that the VOC pattern of CRC patients is altered by curative surgery in a short period, indicating that the exhaled VOCs might be closely related to the presence of CRC. However, to use AeonoseTM as a potential diagnostic tool in the clinical follow-up of CRC patients, the performance of the models needs to be improved through further large-scale prospective research.
Keywords: AeonoseTM; VOCs; colorectal cancer; electronic nose; volatile organic compounds.
Conflict of interest statement
Medical Specialists Company Isala (MSB Isala) invested in the eNose Company, Zutphen, the Netherlands. HLW and WHVNC are members of the MSB, but they declared that they will renounce potential future profits of the eNose Company in person.
Figures
References
-
- Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T., Laurent-Puig P., Quirke P., Yoshino T., Taieb J., et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2020;31:1291–1305. doi: 10.1016/j.annonc.2020.06.022. - DOI - PubMed
-
- Bastiaenen V.P., Hovdenak Jakobsen I., Labianca R., Martling A., Morton D.G., Primrose J.N., Tanis P.J., Laurberg S. Consensus and Controversies regarding Follow-Up After Treatment with Curative Intent of Nonmetastatic Colorectal Cancer: A Synopsis of Guidelines used in Countries Represented in the European Society of Coloproctology. Colorectal. Dis. 2019;21:392–416. doi: 10.1111/codi.14503. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
